Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00016393 | BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | SWOG Cancer Research NetworkNETWORK | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00025194 | Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00036842 | Arsenic Trioxide in Treating Men With Germ Cell Cancer | completed | Phase 2 | — | SWOG Cancer Research NetworkNETWORK | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00070096 | Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00078910 | Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer | completed | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00992186 | A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 46 | Centocor Research & Development, Inc.INDUSTRY | 4 | Jun 24, 2013 | clinicaltrials |
| NCT00003740 | Trastuzumab in Treating Patients With Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT00005952 | Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Duke UniversityOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00019331 | Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00537381 | An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 131 | Centocor, Inc.INDUSTRY | 10 | Jun 20, 2013 | clinicaltrials |
| NCT00045227 | Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00060437 | Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00024232 | Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00006043 | Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00016107 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00039104 | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00558272 | Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease | completed | Phase 2 | 139 | AstraZenecaINDUSTRY | 8 | May 27, 2013 | clinicaltrials |
| NCT01218243 | An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia | completed | Phase 2 | 100 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00077402 | Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 2 | 50 | Cancer Therapeutics Research GroupOTHER | 3 | May 15, 2013 | clinicaltrials |
| NCT00060255 | High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors | completed | Phase 2 | 451 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2013 | clinicaltrials |
| NCT00136526 | Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer | completed | Phase 2 | 30 | University of WashingtonOTHER | 0 | May 9, 2013 | clinicaltrials |
| NCT00095667 | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 8, 2013 | clinicaltrials |
| NCT00403000 | Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | completed | Phase 2 | 27 | Roswell Park Cancer InstituteOTHER | 1 | May 1, 2013 | clinicaltrials |
| NCT00385580 | Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer | completed | Phase 2 | 94 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 30, 2013 | clinicaltrials |
| NCT00924469 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer | completed | Phase 2 | 58 | Janssen Research & Development, LLCINDUSTRY | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00313781 | Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | completed | Phase 2 | 204 | PfizerINDUSTRY | 6 | Apr 11, 2013 | clinicaltrials |
| NCT01012141 | Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer(PROTAXY) | completed | Phase 2 | 30 | Centre Jean PerrinOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00003626 | Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy | completed | Phase 2 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00243048 | Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 70 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01825642 | Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer | completed | Phase 2 / Phase 3 | 140 | University of MichiganOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00046826 | Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy | completed | Phase 2 | — | Nuvance HealthOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00003408 | Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | completed | Phase 2 | 40 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00004211 | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 17 | Duke UniversityOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00244998 | Fulvestrant in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00003173 | High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00103337 | Cilengitide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00757692 | Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00003256 | Flavopiridol in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00027599 | APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00962494 | Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors | completed | Phase 2 | 585 | Stanford UniversityOTHER | 2 | Feb 7, 2013 | clinicaltrials |
| NCT00265070 | Trial of Iressa in Prostate Cancer Patients | completed | Phase 2 | 80 | AstraZenecaINDUSTRY | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00433446 | S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 62 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00276549 | Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00939510 | Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Robert Dreicer MDOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00003832 | Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00074022 | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2013source: clinicaltrials